HealthInvest Partners’s UroGen Pharma URGN Stock Holding History

HealthInvest Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-75,000	Closed	-$1.26M	–	18
2021 Q3	$1.26M	Buy	+75,000	New	+$1.19M	1.89%	16

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

HealthInvest Partners's URGN Position: Q4 2021 in Review

HealthInvest Partners sold out of UroGen Pharma (URGN) in Q4 2021, closing a stake of 75,000 shares — an estimated $1.26M sold.

HealthInvest Partners first reported a position in URGN in Q3 2021 and held it in 1 quarter. The position peaked at $1.26M in Q3 2021. 78 funds tracked by Wall St. Rank hold URGN as of Q4 2021.

HealthInvest Partners reported no remaining UroGen Pharma position as of Q4 2021 after selling out during the quarter.
HealthInvest Partners sold 75,000 UroGen Pharma shares in Q4 2021, an estimated $1.26M.
HealthInvest Partners first reported a position in UroGen Pharma in Q3 2021 and held it in 1 quarter.
HealthInvest Partners's UroGen Pharma position peaked at $1.26M in Q3 2021.
78 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2021.

Based on HealthInvest Partners's 13F filing for Q4 2021, filed 18 Jan 2022.